Catalpol inhibits HHcy-induced EndMT in endothelial cells by modulating ROS/NF-κB signaling
Catalpol inhibits HHcy-induced EndMT, and the underlying mechanism may be related to the ROS/NF-κB signaling pathway. Catalpol may be a potential drug for the treatment of HHcy-related AS.
Authors
- Chengyan Wu (ORCID: https://orcid.org/0009-0000-6006-9075)
- Yuanhao Li (ORCID: https://orcid.org/0000-0002-6938-5012)
- Libo Wang (ORCID: https://orcid.org/0009-0006-2363-6476)
- Shuangshuang Liu (ORCID: https://orcid.org/0000-0001-5204-3529)
- Xuehui Wang
Institutions
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Henan Normal University (CN)
- Henan Medical University (CN)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1186/s12872-024-04046-z
- Citations
- 7
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.00